药物诱导的肝侧腔阻塞综合征:目前的进展和未来的前景
Zaoqin Yu1, Wei Li1, Cheng Tian1
1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Archives of toxicology
|December 24, 2024
概括
药物诱导的肝损伤,特别是肝突阻塞综合征 (HSOS),与某些植物和药物有关. 为了标准化诊断和治疗,需要进一步的研究.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝侧腔阻塞综合征 (HSOS) 是一种罕见的药物诱导性肝损伤 (DILI).
- 血造干细胞移植 (HSCT) 相关的HSOS的知识由于不同的原因,对药物诱导的HSOS的适用性有限.
- 主要原因包括含 pyrrolizidine 化物 (PA) 的植物,化疗和免疫抑制药物.
研究的目的:
- 审查药物诱导的HSOS的关键方面.
- 总结病因,病原,临床特征,诊断,严重程度评估和治疗选择.
主要方法:
- 药物诱导的HSOS的文献综述.
- 概述当前对病理机制的理解.
- 对诊断成像方式的分析.
主要成果:
- 确定的主要病因:含有PA的植物,化疗,免疫抑制剂.
- 突出了非侵入性成像 (超声波,CT,MRI) 在诊断中的作用.
- 指出,我们还没有完全了解病原体,缺乏标准化的分级/治疗方法.
结论:
- 药物诱导的HSOS需要进一步的研究,以标准化严重程度分级和优化治疗策略.
- 了解不同的病因对于管理这种罕见的DILI至关重要.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Hepatic Drug Clearance: Role of Transporters
35
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
35
Hepatic Drug Excretion: Enterohepatic Cycling
996
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
996
Hepatic Drug Excretion: Influencing Factors
80
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
80
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111


